Pipeline Therapeutics to Present Preclinical Poster on PIPE-791 at the Glial Biology: Functional Interactions Among Glia Neurons, a Gordon Research Conference (GRC)

[ad_1] <br><div><div class="article-submitted-content"><p><span class="date">March 6, 2023 4:05 PM</span> | <span> 1 min learn </span></p></div></div><div id="article-body"><p>Pipeline Therapeutics, a clinical-stage biopharmaceutical firm pioneering precision neuroregeneration, introduced immediately that it'll current a poster highlighting the preclinical profile of PIPE-791 on the<b> </b>Glial Biology: Practical Interactions<b> </b>Amongst Glia and Neurons, a Gordon Analysis Convention (GRC), being held March 5-10, 2023, in Ventura, CA.</p><p><b>Poster Presentation Particulars:</b></p><p><b>Title:</b> <i>"</i><i>PIPE-791 inhibits LPA1 to advertise myelination and restrict neuroinflammation"<br/></i><b>Poster Session Date: </b>March 8 and 9, 2023</p><p>The Glial Biology: Practical Interactions Amongst Glia and Neurons GRC is a premier, worldwide scientific convention targeted on advancing the frontiers of science via the presentation of cutting-edge and unpublished analysis.</p><p>Extra info might be discovered on the assembly web site at <a target="_blank" rel="nofollow noopener" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.grc.org%2Fglial-biology-functional-interactions-among-glia-and-neurons-conference%2F2023%2F&esheet=53356117&newsitemid=20230306005139&lan=en-US&anchor=2023+Glial+Biology%3A+Functional+Interactions+Among+Glia+and+Neurons+Conference+GRC&index=1&md5=e007de18160cb082828957fe1b503fa3">2023 Glial Biology: Functional Interactions Among Glia and Neurons Conference GRC</a>.</p> <amp-video-iframe src="https://live.primis-amp.tech/content/video/amp/videoIframe.php?s=109503" width="16" height="9" layout="responsive" dock="#primis-dock-slot" style="overflow: visible;" class="i-amphtml-layout-responsive i-amphtml-layout-size-defined" i-amphtml-layout="responsive"><i-amphtml-sizer style="display:block;padding-top:56.25%"/> </amp-video-iframe> <div class="sc-efaPnb hZQNi"><div class="amp-hubspot-form"><h3 class="amp-hubspot-form__title">ENTER TO WIN $500 IN STOCK OR CRYPTO</h3><p class="amp-hubspot-form__description">Enter your e mail and you may additionally get Benzinga's final morning replace AND a free $30 present card and extra!</p></div></div><p><b>About Pipeline Therapeutics</b></p><p>Pipeline Therapeutics is a clinical-stage biopharmaceutical firm pioneering the event and commercialization of first-in-class therapies for precision neuroregeneration together with myelin restoration, synaptogenesis and axonal restore. The Firm has a broad pipeline of packages to deal with a number of CNS problems. Its flagship program, PIPE-307, has accomplished two Part 1 scientific trials - a SAD/MAD examine and a PET examine - in wholesome volunteers, and has acquired Investigational New Drug clearance from the Meals and Drug Administration to provoke scientific improvement in relapsing-remitting MS sufferers.</p><p>For extra info, please go to <a target="_blank" rel="nofollow noopener" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.pipelinetherapeutics.com%2F&esheet=53356117&newsitemid=20230306005139&lan=en-US&anchor=www.pipelinetherapeutics.com&index=2&md5=e9761089739ac36481150b71b5aae069">www.pipelinetherapeutics.com</a> and have interaction with us on LinkedIn.</p><amp-fx-flying-carpet height="600" data-reactroot="" class="i-amphtml-layout-fixed-height i-amphtml-layout-size-defined" style="height:600px;" i-amphtml-layout="fixed-height"><amp-ad data-block-on-consent="" data-lazy-fetch="true" data-slot="/15188745,4107070/Benzinga-AMP/AMP-FlyingCarpet" height="600" layout="fixed" rtc-config="{"urls":["https://api.floors.dev/sgw/v1/amp/floors?k=QBNaieBwWeBYMRGsreCNdCsuWLTtmZ&data-slot=/15188745/Benzinga-AMP/AMP-FlyingCarpet"],"vendors":{"aps":{"PARAMS":{"amp":"1"},"PUB_ID":"600","PUB_UUID":"16268e26-dabe-4bf4-a28f-b8f4ee192ed3"},"criteo":{"NETWORK_ID":4905,"PUBLISHER_SUB_ID":"Benzinga-AMP-FlyingCarpet","ZONE_ID":1382492},"medianet":{"CID":"8CU8ZT2C4"},"t13":{"ACCOUNT_ID":"9a3c6c23-453a-4cba-b419-30b908f39a50","TAG_ID":"f62c6d8b-6b03-4ae3-a4f0-d8b1f6631f58"}}}" type="doubleclick" width="300" class="i-amphtml-layout-fixed i-amphtml-layout-size-defined" style="width:300px;height:600px;" i-amphtml-layout="fixed"/></amp-fx-flying-carpet><p id="mmgallerylink"> View supply model on businesswire.com: <a target="_blank" href="https://www.businesswire.com/news/home/20230306005139/en/" rel="nofollow noopener">https://www.businesswire.com/news/home/20230306005139/en/</a> </p></div><p>© 2023 Benzinga.com. Benzinga doesn't present funding recommendation. All rights reserved.</p> <br>[ad_2] <br><a href="https://www.benzinga.com/amp/content/31225659">Source link </a>